Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
The third generation AKR1C3-activated prodrug, ACHM-025, ... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia
0
Authors
C. Toscan
23 more
C. Toscan
•
Hannah McCalmont
21 more
•
Richard Lock
Published
November 6, 2024
Paper
Conversation
0
Reviews
0
Bounties
0
Abstract
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Blood Cancer Journal
Topics
Medicine
Cancer Oncology
Physiology
Internal Medicine
Cell Biology
Show all topics
DOI
10.1038/s41408-024-01180-x
License
CC-BY-NC-ND
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Blood Cancer Journal
Topics
Medicine
Cancer Oncology
Physiology
Internal Medicine
Cell Biology
Show all topics
DOI
10.1038/s41408-024-01180-x
License
CC-BY-NC-ND
